PSE
20.4.2021 13:49:12 CEST | Business Wire | Press release
Process Systems Enterprise (PSE), a Siemens business, today released its rebranded gPROMS Process advanced process modelling environment.
Formerly known as gPROMS ProcessBuilder, gPROMS Process 2.0 is the first major release since PSE was acquired by Siemens. Eckard Eberle, CEO of Siemens Digital Industries Process Automation division, says “the significantly enhanced capabilities and functionality you see in this release reflect the substantial investment Siemens is making into product development within PSE to provide the process industries with a new generation of digital tools.”
Costas Pantelides, PSE CEO and architect of the gPROMS platform, says “The name change signifies a break with the past. Until now, ProcessBuilder has been an environment for sophisticated users who are typically running high-value, complex optimizations. This is the first release in a major, multi-year development programme that will bring the cutting-edge capabilities of the gPROMS platform to users across process organisations”.
The release contains significant new model library content, including a new polyolefins library to support online nonlinear control applications for polymers such as LDPE and HDPE; an advanced model library for electrochemical reactors to support the optimization of clean energy and hydrogen systems; a data-driven model library for hybrid modelling combining data-driven elements with first-principles models; new batch distillation and decanter models for specialty chemicals; enhancements to the multistream heat exchanger for LNG and cryogenic process optimization and to PSE’s industry-leading catalytic reactors model library; and a unique new cyclic steady-state solver to speed up modelling of adsorption processes.
gPROMS Process includes an all-new integral gPROMS Properties package containing all industry-standard thermodynamic models plus PSE’s industry-leading SAFT-γ Mie, which allows accurate prediction of physical properties and phase behaviour with minimal experimental data. “We aim to provide the world’s leading materials modelling capability within a process simulator”, says Pantelides. “covering strongly associating, polymer and active pharmaceutical ingredient systems within a single properties package”.
gPROMS Process also supports the automatic generation of fast-solving surrogate models, technology already extensively proven on large-scale, multi-site optimization projects. A new interface to Siemens’ STAR-CCM+ simplifies combining process and CFD hydrodynamic models for detailed equipment design. Support for the gPROMS Web Applications Platform (gWAP) makes it easy to supply models to users across the organisation via web interfaces.
gPROMS Process is unique among process simulation tools in that it was designed from the start to support the entire process lifecycle, from R&D to operations. Its comprehensive digital design capability makes it possible to explore the process decision space rapidly and effectively, and determine optimal values for multiple design variables simultaneously to arrive at truly optimized designs in the minimum time. gPROMS Process models can be exported for implementation online within the gPROMS Digital Applications Platform (gDAP), for real-time monitoring, soft-sensing and real-time optimization applications coupled with plant data.
About: www.psenterprise.com/news/pressroom
View source version on businesswire.com: https://www.businesswire.com/news/home/20210420005688/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FlexTrade Expands Portfolio Risk and Analytics Capabilities Through Strategic Partnership with Portx13.7.2026 15:30:00 CEST | Press release
The collaboration expands FlexTrade’s front-office risk analytics offering, connecting portfolio construction, risk insight, and trading decisions in a unified buy-side workflow. FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems, and Portx, an advanced portfolio construction and analytics provider, today announced the integration of Portx’sreal-time portfolio construction, optimization, and risk analytics capabilities into FlexTrade’s integrated buy-side order and execution management system (OEMS), FlexONE. The partnership comes as buy-side firms place greater emphasis on real-time risk management across increasingly complex portfolios, advanced hedging strategies, and supporting operating models. For hedge funds and institutional asset managers, particularly those running multi-strategy or multi-asset approaches, the ability to assess portfolio risk, review pro forma exposures, and act on those insights within the order and executio
Xsolla Connect Returns to Brighton13.7.2026 15:22:00 CEST | Press release
Connecting The UK Game Development Community For Networking And Insights During Develop:Brighton Xsolla, a global video game commerce company, today announced the launch of an exclusive networking event for the UK game development community, Xsolla Connect, taking place with Develop:Brighton 2026 on July 15, 2026. Designed to bring together independent and mid-tier developers, publishers, investors, and industry professionals, the event will offer a focused evening of meaningful connections and actionable insights at one of the UK’s most important annual games gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713748542/en/ Graphic: Xsolla Develop:Brighton has long served as a cornerstone of the European video games industry, drawing developers, publishers, investors, and studio leaders from across the UK and beyond to share knowledge, explore opportunities, and forge lasting business relationships. Xsolla’s event
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release
Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 14:00:00 CEST | Press release
Integrated subsea production system and local capabilities enable accelerated deepwater development Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, um
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 14:00:00 CEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom